Abstract 426P
Background
The support for caregivers (CG) of patients with cancer is an essential factor for maintaining the safety and continuity of palliative chemotherapy. Because of insufficient knowledge regarding their QOL, there are no durable strategies for supporting CGs during the treatment.
Methods
We aimed to assess the QOL of the CGs of patients with cancer undergoing palliative chemotherapy. This single-institution, prospective, observational study was approvedby the institutional review board of Ina Central Hospital on July 20th 2016. Total 102 patients undergoing palliative chemotherapy (64 male and 38 female patients; mean age 68.8 years) and their CGs (30 maleand 72 female; mean age 64.3 years) were included. The primary lesions in the patients were pancreatic in 30, colorectal in 21, stomach or duodenal in 21, oesophageal in 18, and biliary in 12. We used EORTC QL-C-30 to assess the QOL of patients and CGs at the beginning of the first-line chemotherapy. A total of 29 of 102 pairs of patients and CGs were assessed at the beginning of the first and second-line chemotherapies. According to a formula incorporating measures of clinical symptoms and comprehensive scales of physical function (PF), role function (RF), emotional function (EF), cognitive function (CF), and social function. In addition, a summary score (SS) and a global health scale (GHS) on QOL were computed using comprehensive scales.
Results
All the parameters assessed in CGs yielded higher values than those for patients; however, EF and CF did not show significant differences between patients and CGs. Among longitudinal observed pairs, discrepancies in GHS and SS between patients and CGs were identified in 38 % and 34%, respectively. Those CGs who did not demonstrate an improvement in GHS compared with those who showed an improvement in this parameter had lower PF and RF values at the beginning of the treatment.
Conclusions
Even at the beginning of the treatment, the CGs of patients with cancer undergoing palliative chemotherapy showed impairment in daily QOL. In addition, emotional and cognitive functions were impaired as much as patients. CGs with physical difficulty and role function impairment in family should be monitored for worsening of their QOL during the course of treatment.
Clinical trial identification
Editorial acknowledgement
This has been edited for English language, grammar, punctuation, and spelling by Enago, the editing brand of Crimson Interactive Pvt. Ltd under Normal Editing.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract